Pharmaceutical Technology
FEBRUARY 29, 2024
India’s Tata Institute has developed a tablet combining resveratrol and copper that has the potential to prevent the recurrence of cancer.
AuroBlog - Aurous Healthcare Clinical Trials blog
FEBRUARY 29, 2024
Even small doses of LSD could have therapeutic benefits for mental health and task performance, a new study shows. Researchers from the US and Germany gave 21 adults either a placebo or 13 or 26 micrograms of LSD – small doses that rarely lead to hallucinatory effects.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
FEBRUARY 29, 2024
LUT014 is being investigated in an ongoing Phase II trial as a first-line treatment for EGFR inhibitor-induced acneiform rash, for which there is no approved drug.
Bio Pharma Dive
FEBRUARY 29, 2024
The startup, Kenai Therapeutics, has raised $82 million and will be chaired by Jeff Jonas, a new Cure partner and former CEO of Sage Therapeutics.
Advertisement
There’s been a rapid shift towards decentralization in clinical trials & it’s clear why. The potential for reaching a larger pool of recruits is possible when sponsors can bring more trial activities to the patient. Tele visits, digital consent, new monitoring sensors, & direct-to-patient supply are virtual tools that existed before the pandemic, but now there’s swift adoption of these methods because they’ve been proven to help launch & complete trials more effectively.
Pharmaceutical Technology
FEBRUARY 29, 2024
Amyotrophic lateral sclerosis (ALS) is a swiftly advancing, fatal neurodegenerative condition marked by muscle weakness, atrophy, and spasticity.
AuroBlog - Aurous Healthcare Clinical Trials blog
FEBRUARY 29, 2024
The Central Drugs Standard Control Organisation (CDSCO) has declared almost 5 per cent of the total drug samples it tested during the month of January, 2024 as Not of Standard Quality (NSQ). The number of samples tested, however, has declined during the month compared to the previous months.
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
Bio Pharma Dive
FEBRUARY 29, 2024
The unusual deal will see one of the investment firm’s startups work with Gilead to expand the cancer drug’s label, with Abingworth receiving payment if successful.
Pharmaceutical Technology
FEBRUARY 29, 2024
The US HHS Secretary called for state collaboration on a project to improve gene therapy access for sickle cell disease.
Pharma Times
FEBRUARY 29, 2024
Aphasia is a language disorder caused by some form of brain damage, including stroke
Bio Pharma Dive
FEBRUARY 29, 2024
Less than two years after Bristol Myers bought Turning Point for $4.1 billion, Jean Cui and Peter Li have built a new startup that’s brought in more than $170 million in funding.
Advertiser: FourKites
A research study conducted by The Journal of Commerce and FourKites surveyed hundreds of international shippers, exploring how their usage of global supply chain visibility technology has evolved since the onset of global disruptions caused by COVID-19. For international shippers, ocean freight visibility has evolved from optional to essential and satisfaction with visibility varies greatly depending on how it is obtained and delivered.
Pharma Times
FEBRUARY 29, 2024
Approximately 80% of patients taking Remicade from diagnosis had symptoms controlled
Pharmaceutical Technology
FEBRUARY 29, 2024
After a challenging few years post-pandemic, industry professionals believe diagnostic testing is back on track
Fierce Pharma
FEBRUARY 29, 2024
In what CEO Albert Bourla called an update to a top priority at Pfizer, the company on Thursday systemically laid out its new oncology strategy following the $43 billion acquisition of antibody-dru | Pfizer on Thursday systemically laid out its new oncology strategy following the $43 billion acquisition of Seagen. The company aims to have at least eight blockbuster cancer drugs by 2030, with a focus on four main cancer types.
Pharmaceutical Technology
FEBRUARY 29, 2024
For Indena, the leading company dedicated to the identification, development and production of high-quality active principles derived from plants, custom services have been a key area of expertise for some time now.
Speaker: Steve Goldstein, Sales Leader
Are you currently in sales, or involved in a business that depends on strong sales results? What about the extremely competitive world of medical device sales? What are some of the top challenges your customers face and how do you approach understanding what’s most important to them? Join Steve Goldstein, Sales Success Coach, Motivational Speaker and Medical Device Sales Leader from Gold Selling LLC., to discover critical strategies and approaches you can take to engage your customers, achieve g
pharmaphorum
FEBRUARY 29, 2024
Explore how innovation in healthcare can be scaled across hospitals and nations, driving transformation through research & development, biotech collaborations, and fostering start-ups in the industry.
Pharmaceutical Technology
FEBRUARY 29, 2024
An Eli Lilly-sponsored GlobalData report finds that obese workers had $6,472 higher annual in medical and economic costs.
pharmaphorum
FEBRUARY 29, 2024
Explore the impact of the Inflation Reduction Act (IRA) on drug prices and negotiations within the life sciences industry, as it stands on the threshold of change. Gain insights into the potential outcomes and implications of this legislation.
Pharmaceutical Technology
FEBRUARY 29, 2024
Indena CDMO origin: Founded in 1921 by Carlo Boccaccio Inverni and Biagio Alberto Della Beffa and headquartered in Milan, Indena…
pharmaphorum
FEBRUARY 29, 2024
Learn more about Marcus West and his company, 60 Seconds, specialising in coaching services to help individuals and teams reach their full potential.
Pharmaceutical Technology
FEBRUARY 29, 2024
Research published by the British Medical Journal on 28 February 2024, has found that ultra-processed foods (UPFs), including cereals, chocolate bars, and ready meals, are linked to 32 negative health outcomes.
Antidote
FEBRUARY 29, 2024
Rare Disease Day, typically observed on February 28th, will be celebrated this year on February 29th! Rare Disease Day is an awareness holiday intended to generate change for the 300 million people who are diagnosed with a rare disease worldwide, as well as their families and caregivers.
Pharmaceutical Technology
FEBRUARY 29, 2024
Every Cure has received $48.3m contract from the ARPA-H, marking a significant federal investment in drug repurposing.
pharmaphorum
FEBRUARY 29, 2024
It’s been a couple of months since pharma’s annual JP Morgan Chase Healthcare Conference, where the mood around pharma M&A this year was optimistic, albeit with a few caveats. On today’s podcast, host Jonah Comstock is joined by Cody Powers, principal of portfolio and business development at ZS Associates, to discuss those trends and predictions and how they’re shaking out so far.
Pharmaceutical Technology
FEBRUARY 29, 2024
The UK MHRA has announced new process changes in its latest guidance for enhancing the efficiency of assessing established therapies.
BioPharma Reporter
FEBRUARY 29, 2024
Being able to identify rare diseases is a challenging aspect especially since more than 80% of them have genetic origins.
pharmaphorum
FEBRUARY 29, 2024
Palatin Technologies’ therapy for dry eye disease (DED) missed its primary endpoints in a phase 3 trial, knocking investor confidence as it tries to chart a way forward.
Outsourcing Pharma
FEBRUARY 29, 2024
Yesterday, (February 28), a clinical-stage biotechnology company, Redx, announced that the first participant has been dosed in a phase 1 clinical trial for RXC008.
pharmaphorum
FEBRUARY 29, 2024
On Rare Disease Day, Clinigen has launched a campaign to try to encourage doctors and patients to explore how they can get early access to investigational therapies.
Fierce Pharma
FEBRUARY 29, 2024
Venture capital firms pitching in on drug development isn’t exactly a new way of doing business for the biopharma industry. | Venture capital firms pitching in on drug development isn’t exactly a new way of doing business for the biopharma industry. But a new funding pact between Carlyle’s Abingworth and Gilead Sciences is somewhat unconventional.
pharmaphorum
FEBRUARY 29, 2024
Ironwood Pharma says phase 3 trial of apraglutide in short bowel syndrome (SBS) hit it main endpoint, but missed secondary outcomes weigh on its share price
XTalks
FEBRUARY 29, 2024
Dual-function fusion proteins represent a cutting-edge approach in biopharmaceutical research, offering a promising avenue for the development of novel therapeutics in the treatment of complex diseases such as cancer and autoimmune disorders. These innovative molecules are engineered by combining two or more functional domains from different proteins into a single, cohesive unit, enabling them to perform multiple biological activities simultaneously.
pharmaphorum
FEBRUARY 29, 2024
Almost four years after it was approved in Europe to treat the incurable rare disease systemic amyloid light-chain (AL) amyloidosis, Johnson & Johnson’s Darzalex has been given the go-ahead for routine use by the NHS in England and Wales.
Fierce Pharma
FEBRUARY 29, 2024
As Johnson & Johnson's U.S. exclusivity period on its immunology blockbuster Stelara ticks away, another biosimilar player has lined up for the piece of the drug's sales pie. | As Johnson & Johnson's U.S. exclusivity period on Stelara ticks away, another biosimilar player has lined up for the piece of the blockbuster's sales pie.
pharmaphorum
FEBRUARY 29, 2024
Generic and biosimilar drugmaker Sandoz has agreed to pay $265 million to settle allegations of price-fixing in a Pennsylvania lawsuit.
Expert insights. Personalized for you.
358 
Let's personalize your content